{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:21:07Z","timestamp":1787023267863,"version":"build-2736575974"},"reference-count":19,"publisher":"Tohoku University Medical Press","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2010]]},"DOI":"10.1620\/tjem.220.121","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T01:04:14Z","timestamp":1265591054000},"page":"121-126","source":"Crossref","is-referenced-by-count":33,"title":["Gemtuzumab Ozogamicin Therapy for Isolated Extramedullary AML Relapse after Allogeneic Hematopoietic Stem-Cell Transplantation"],"prefix":"10.1620","volume":"220","author":[{"given":"Toshihiko","family":"Ando","sequence":"first","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Mitani","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimie","family":"Matsunaga","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuki","family":"Nakazora","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Gondo","sequence":"additional","affiliation":[{"name":"First Department of Pathology, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Yujiri","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Tanizawa","sequence":"additional","affiliation":[{"name":"Third Department of Internal Medicine, Yamaguchi University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","unstructured":"B&eacute;k&aacute;ssy, A.N., Hermans, J., Gorin, N.C. &amp; Gratwohl, A. (1996) Granulocytic sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. <i>Bone Marrow Transplant<\/i>., <b>17<\/b>, 801-808."},{"key":"2","doi-asserted-by":"crossref","unstructured":"Berthou, C., Leglise, M.C., Herry, A., Balcon, D., Hardy, E., Lessard, M. &amp; Abgrall, J-F. (1998) Extramedullary relapse after favorable molecular response to donor leukocyte infusions for recurring acute leukemia. <i>Leukemia<\/i>, <b>12<\/b>, 1676-1681.","DOI":"10.1038\/sj.leu.2401144"},{"key":"3","unstructured":"Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G. &amp; Pazdur, R. (2001) Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. <i>Clin. Cancer Res.<\/i>, <b>7<\/b>, 1490-1496."},{"key":"4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702659"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Dinndorf, P.A., Andrews, R.G., Benjamin, D., Ridgway, D., Wolff, L. &amp; Bernstein, I.D. (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. <i>Blood<\/i>, <b>67<\/b>, 1048-1053.","DOI":"10.1182\/blood.V67.4.1048.1048"},{"key":"6","doi-asserted-by":"publisher","DOI":"10.1021\/bc010021y"},{"key":"7","unstructured":"Jiang, Y.Z., Cullis, J.O., Kanfer, E.J., Goldman, J.M. &amp; Barrett, A.J. (1993) T cell and NK cell mediated graft-versus-leukaemia reactivity following donor buffy coat transfusion to treat relapse after marrow transplantation for chronic myeloid leukaemia. <i>Bone Marrow Transplant.<\/i>, <b>11<\/b>, 133-138."},{"key":"8","doi-asserted-by":"crossref","unstructured":"Jilani, I., Estey, E., Huh, Y., Joe, Y., Manshouri, T., Yared, M., Giles, F., Kantarjian, H., Cortes, J., Thomas, D., Keating, M., Freireich, E. &amp; Albitar, M. (2002) Differences in CD33 intensity between various myeloid neoplasms. <i>Am. J. Clin. Pathol.<\/i>, <b>118<\/b>, 560-566.","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402677"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Larson, R.A., Sievers, E.L., Stadtmauer, E.A., L&ouml;wenberg, B., Estey, E.H., Dombret, H., Theobald, M., Voliotis, D., Bennett, J.M., Richie, M., Leopold, L.H., Berger, M.S., Sherman, M.L., Loken, M.R., van Dongen, J.J., Bernstein, I.D. &amp; Appelbaum, F.R. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. <i>Cancer<\/i>, <b>104<\/b>, 1442-1452.","DOI":"10.1002\/cncr.21326"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Mortimer, J., Blinder, M.A., Schulman, S., Appelbaum, F.R., Buckner, C.D., Clift, R.A., Sanders, J.E., Storb, R. &amp; Thomas, E.D. (1989) Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. <i>J. Clin. Oncol.<\/i>, <b>7<\/b>, 50-57.","DOI":"10.1200\/JCO.1989.7.1.50"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Owonikoko, T., Agha, M., Balassanian, R., Smith, R. &amp; Raptis, A. (2007) Gemtuzumab therapy for isolated extramedullary AML relapse following allogeneic stem-cell transplant. <i>Nat. Clin. Pract. Oncol.<\/i>, <b>4<\/b>, 491-495.","DOI":"10.1038\/ncponc0899"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Piccaluga, P.P., Martinelli, G., Rondoni, M., Malagola, M., Gaitani, S., Isidori, A., Bonini, A., Gugliotta, L., Luppi, M., Morselli, M., Sparaventi, G., Visani, G. &amp; Baccarani, M. (2004) Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomas. <i>Leuk. Lymphoma<\/i>, <b>45<\/b>, 1791-1795.","DOI":"10.1080\/1042819042000219485"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Sievers, E.L., Appelbaum, F.R., Spielberger, R.T., Forman, S.J., Flowers, D., Smith, F.O., Shannon-Dorcy, K., Berger, M.S. &amp; Bernstein, I.D. (1999) Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. <i>Blood<\/i>, <b>93<\/b>, 3678-3684.","DOI":"10.1182\/blood.V93.11.3678"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Sievers, E.L., Larson, R.A., Stadtmauer, E.A., Estey, E., L&ouml;wenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J.M., Sherman, M.L., Berger, M.S., Eten, C.B., Loken, M.R., van Dongen, J.J., Bernstein, I.D. &amp; Appelbaum, F.R; Mylotarg Study Group. (2001) Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. <i>J. Clin. Oncol.<\/i>, <b>19<\/b>, 3244-3254.","DOI":"10.1200\/JCO.2001.19.13.3244"},{"key":"16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701319"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Sullivan, K.M., Weiden, P.L., Storb, R., Witherspoon, R.P., Fefer, A., Fisher, L., Buckner, C.D., Anasetti, C., Appelbaum, F.R., Badger, C., Beatty, P., Bensinger, W., Berenson, R., Bigelow, C., Cheever, M.A., Clift, R., Deeg, H.J., Doney, K., Greenberg, P., Hansen, J.A., Hill, R., Loughran, T., Martin, P., Neiman, P., Petersen, F.B., Sanders, J., Singer, J., Stewart, P. &amp; Thomas, E.D. (1989) Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. <i>Blood<\/i>, <b>73<\/b>, 1720-1728.","DOI":"10.1182\/blood.V73.6.1720.1720"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Wadleigh, M., Richardson, P.G., Zahrieh, D., Lee, S.J., Cutler, C., Ho, V., Alyea, E.P., Antin, J.H., Stone, R.M., Soiffer, R.J. &amp; DeAngelo, D.J. (2003) Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. <i>Blood<\/i>, <b>102<\/b>, 1578-1582.","DOI":"10.1182\/blood-2003-01-0255"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1126\/science.2717946"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/tjem\/220\/2\/220_2_121\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,28]],"date-time":"2021-04-28T15:34:10Z","timestamp":1619624050000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/tjem\/220\/2\/220_2_121\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.220.121","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010]]}}}